Exagen Inc Aktie News

Erzielte Rekordumsatz, Testvolumen und 12-Monats-Durchschnittserlös Verringerte den Nettoverlust um fast 30 % und reduzierte den bereinigten EBITDA-Verlust auf 0,1 Mio. Erhöhte die Umsatzprognose für das Gesamtjahr auf 72 - 75 Mio. CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), ein führender Anbieter von Diagnoselösungen für Autoimmunerkrankungen, berichtete heut...

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWI...

Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.

CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2026, and recent corporate updates.

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended March 31, 2026, before the market opens on Monday, May 11, 2026.